Alzamend Neuro, Inc. 10-Q

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS Recent Sales of Unregistered Equity Securities During the quarter ended January 31, 2022, we issued 1,000,000 shares of Common Stock upon the exercise of stock options. During the quarter ended January 31, 2022, we issued 252,265 shares of Common Stock upon the conversion of $378,373 of principal and accrued interest of a convertible promissory note previously issued. Use of Proceeds from Initial Public Offering On June 15, 2021, the Company issued and sold 2,875,000 shares of Common Stock in the IPO at a public offering price of $5.00 per share, resulting in net proceeds of $12.9 million after deducting underwriting discounts and commissions and offering expenses paid by the Company. There has been no material change in our planned use of the net proceeds from our IPO as described in our final prospectus filed pursuant to Rule 424(b)(4) under the Securities Act with the SEC. As of January 31, 2022, we have used $5.0 million of the net proceeds from the IPO. ITEM 3. DEFAULTS UPON SENIOR SECURITIES None. ITEM 4. MINE SAFETY DISCLOSURES Not applicable.